Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral
dose of eleclazine and its metabolite, GS-623134, in participants with normal and impaired
renal function. Participants in the healthy control group will be matched to participants
with impaired renal function by age (± 5 years), gender, and body mass index (± 10%).